Literature DB >> 17483354

Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.

Shanthi Ganesh1, Melissa Gonzalez Edick, Neeraja Idamakanti, Marina Abramova, Melinda Vanroey, Michael Robinson, Chae-Ok Yun, Karin Jooss.   

Abstract

Selective replication of oncolytic viruses in tumor cells provides a promising approach for the treatment of human cancers. One of the limitations observed with oncolytic viruses currently used in the treatment of solid tumors is the inefficient spread of virus throughout the tumor mass following intratumoral injection. Data are presented showing that oncolytic adenoviruses expressing the relaxin gene and containing an Ad5/Ad35 chimeric fiber showed significantly enhanced transduction and increased virus spread throughout the tumor when compared with non-relaxin-expressing, Ad5-based viruses. The increased spread of such viruses throughout tumors correlated well with improved antitumor efficacy and overall survival in two highly metastatic tumor models. Furthermore, nonreplicating viruses expressing relaxin did not increase metastases, suggesting that high level expression of relaxin will not enhance metastatic spread of tumors. In summary, the data show that relaxin may play a role in rearranging matrix components within tumors, which helps recombinant oncolytic adenoviruses to spread effectively throughout the tumor mass and thereby increase the extent of viral replication within the tumor. Expressing relaxin from Ad5/Ad35 fiber chimeric adenoviruses may prove a potent and novel approach to treating patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483354     DOI: 10.1158/0008-5472.CAN-06-4260

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

2.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

3.  The novel gene HA117 promotes in vitro and in vivo drug resistance in mouse colon tumor cells.

Authors:  Y X Guo; Y H Xu; G H Zheng; X Q Jin
Journal:  Cancer Gene Ther       Date:  2017-07-21       Impact factor: 5.987

Review 4.  Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Crit Rev Biomed Eng       Date:  2012

5.  Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Authors:  Sonia Guedan; Juan José Rojas; Alena Gros; Elena Mercade; Manel Cascallo; Ramon Alemany
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

Review 6.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

Review 7.  Exploring the tumor microenvironment with nanoparticles.

Authors:  Lei Miao; Leaf Huang
Journal:  Cancer Treat Res       Date:  2015

8.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

9.  The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Authors:  C Puig-Saus; E Laborda; A Rodríguez-García; M Cascalló; R Moreno; R Alemany
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

Review 10.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.